Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress

Immutep ( (IMMP) ) has issued an announcement.

On March 19, 2026, Immutep reported positive progress from its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, in healthy participants. The company has completed the single ascending dose phase with dosing up to 14 mg/kg, reporting that IMP761 was well tolerated at all dose levels and showed a clear, durable immunosuppressive effect on T-cell–mediated responses to foreign antigen challenge.

The multiple ascending dose phase is under way to further assess pharmacokinetics and safety, with completion expected in the third quarter of 2026 and full Phase I data to be presented at the EULAR congress in London on June 4, 2026. As the first LAG-3 agonist antibody designed to selectively silence pathogenic memory T cells at sites of chronic inflammation, IMP761 could position Immutep as a pioneer in a novel therapeutic class for multi-billion-dollar autoimmune markets, potentially offering more targeted treatment with fewer adverse effects for patients and a significant value driver for shareholders if later-stage trials are successful.

The most recent analyst rating on (IMMP) stock is a Hold with a $0.39 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

The score is primarily held down by weak financial performance (ongoing losses and negative cash flows) and bearish technical momentum (very low RSI/Stochastic and negative MACD). Valuation is also constrained by a negative P/E that reflects unprofitability and no dividend support.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep Limited is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases, with a strategic focus on drugs that modulate the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. The company’s portfolio aims either to stimulate or suppress immune responses, targeting large and growing markets such as rheumatoid arthritis, Type 1 diabetes, multiple sclerosis and various cancers.

Average Trading Volume: 1,303,760

Technical Sentiment Signal: Sell

Current Market Cap: $53.24M

Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.